Logo image
Sign in
Changes in Tumor Blood Flow as Measured by Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) May Predict Activity of Single Agent Bevacizumab in Recurrent Epithelial Ovarian (EOC) and Primary Peritoneal Cancer (PPC) Patients: An exploratory analysis of a Gynecologic Oncology Group Phase II study
Journal article

Changes in Tumor Blood Flow as Measured by Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) May Predict Activity of Single Agent Bevacizumab in Recurrent Epithelial Ovarian (EOC) and Primary Peritoneal Cancer (PPC) Patients: An exploratory analysis of a Gynecologic Oncology Group Phase II study

Dana M. Chase, Michael W. Sill, Bradley J. Monk, Mark D. Chambers, Kathleen M. Darcy, Ernest S. Han, Barbara J. Buening, Joel I. Sorosky, John P. Fruehauf and Robert A. Burger
Gynecologic Oncology, Vol.126(3), pp.375-380
09/2012
PMID: 22683587

Metrics

4 Record Views

Details